8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The association between obesity with serum levels of liver enzymes, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and gamma‐glutamyl transferase in adult women

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Obesity‐induced inflammation may independently disturb the function of critical organs such as liver. This study aimed to investigate the association of obesity with serum levels of biomarkers of liver function including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and gamma‐glutamyl transferase (GGT) in adult women.

          Methods

          This cross‐sectional study was carried out on 360 adult women in the summer of 2020 in Tehran, Iran. The participants were categorized into two groups based on their body mass index (BMI≤29.9 and BMI > 30). The serum levels of ALT, AST, ALP and GGT were measured. Logistic regression method was used to assess the association between BMI and liver enzymes after adjusting for the confounders.

          Results

          The mean BMI in non‐obese and obese groups was 26.32 ± 2.61 and 33.40 ± 2.80 kg/m 2, respectively ( p = .01). A significant association was found between BMI with ALT ( β = .16, p = .002) and GGT ( β = .19, p = .01) enzymes after adjustment for age. The association between BMI and GGT remained significant after further adjustments for smoking, alcohol use, physical activity and educational status. There was no significant association between BMI and liver enzymes after adjustment for dietary intake.

          Conclusions

          Obesity was associated with the level of serum liver enzymes. However, adjustment for dietary intake disappeared the significant results. Further studies are needed to determine the independent effects of obesity on the liver function.

          Abstract

          The results of the present study indicated that there was a positive association between BMI and serum level of GGT and ALT after adjustment with confounding variable of age. The association between BMI and GGT remained significant after adjusting for smoking status, alcohol use, physical activity, and educational status. There was no significant association between BMI and liver enzymes after further adjustment for dietary intake of calorie, protein, carbohydrate, and fat.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Adipokines in inflammation and metabolic disease.

          The worldwide epidemic of obesity has brought considerable attention to research aimed at understanding the biology of adipocytes (fat cells) and the events occurring in adipose tissue (fat) and in the bodies of obese individuals. Accumulating evidence indicates that obesity causes chronic low-grade inflammation and that this contributes to systemic metabolic dysfunction that is associated with obesity-linked disorders. Adipose tissue functions as a key endocrine organ by releasing multiple bioactive substances, known as adipose-derived secreted factors or adipokines, that have pro-inflammatory or anti-inflammatory activities. Dysregulated production or secretion of these adipokines owing to adipose tissue dysfunction can contribute to the pathogenesis of obesity-linked complications. In this Review, we focus on the role of adipokines in inflammatory responses and discuss their potential as regulators of metabolic function.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Inflammatory mechanisms in obesity.

            The modern rise in obesity and its strong association with insulin resistance and type 2 diabetes have elicited interest in the underlying mechanisms of these pathologies. The discovery that obesity itself results in an inflammatory state in metabolic tissues ushered in a research field that examines the inflammatory mechanisms in obesity. Here, we summarize the unique features of this metabolic inflammatory state, termed metaflammation and defined as low-grade, chronic inflammation orchestrated by metabolic cells in response to excess nutrients and energy. We explore the effects of such inflammation in metabolic tissues including adipose, liver, muscle, pancreas, and brain and its contribution to insulin resistance and metabolic dysfunction. Another area in which many unknowns still exist is the origin or mechanism of initiation of inflammatory signaling in obesity. We discuss signals or triggers to the inflammatory response, including the possibility of endoplasmic reticulum stress as an important contributor to metaflammation. Finally, we examine anti-inflammatory therapies for their potential in the treatment of obesity-related insulin resistance and glucose intolerance.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics

              The obesity epidemic is closely associated with the rising prevalence and severity of nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple steatosis (SS), but also with advanced disease, i.e., nonalcoholic steatohepatitis (NASH), NASH-related cirrhosis and hepatocellular carcinoma. As a consequence, apart from increasing all-cause mortality, obesity seems to increase liver-specific mortality in NAFLD patients. Given the lack of approved pharmacological interventions for NAFLD, targeting obesity is a rational option for its management. As the first step, lifestyle modification (diet and exercise) is recommended, although it is difficult to achieve and sustain. When the first step fails, adding pharmacotherapy is recommended. Several anti-obesity medications have been investigated in NAFLD (e.g., orlistat, glucagon-like peptide-1 analogs), other anti-obesity medications have not been investigated (e.g., lorcaserin, phentermine hydrochloric, phentermine/topiramate and naltrexone/bupropion), whereas some medications with weight-lowering efficacy have not been approved for obesity (e.g., sodium-glucose cotransporter-2 inhibitors, farnesoid X receptor ligands). If the combination of lifestyle modification and pharmacotherapy also fails, then bariatric surgery should be considered in selected morbidly obese individuals. This review summarizes best evidence linking obesity with NAFLD and presents related therapeutic options.
                Bookmark

                Author and article information

                Contributors
                minaesmaeili864@yahoo.com
                sdoaee@yahoo.com
                Journal
                Endocrinol Diabetes Metab
                Endocrinol Diabetes Metab
                10.1002/(ISSN)2398-9238
                EDM2
                Endocrinology, Diabetes & Metabolism
                John Wiley and Sons Inc. (Hoboken )
                2398-9238
                30 August 2022
                November 2022
                : 5
                : 6 ( doiID: 10.1002/edm2.v5.6 )
                : e367
                Affiliations
                [ 1 ] Faculty of Medicine Urmia University of Medical sciences Urmia Iran
                [ 2 ] Department of Food and Beverage Products Food and Drug Administration Tehran Iran
                [ 3 ] Department of Clinical Nutrition, School of Nutrition and Food Sciences Shiraz University of Medical Sciences Shiraz Iran
                [ 4 ] Cancer Research Center Shahid Beheshti University of Medical Sciences Tehran Iran
                [ 5 ] Department of Food and Nutrition Policy and Planning National Nutrition and Food Technology Research Institute, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences Tehran Iran
                [ 6 ] Department of Nutrition Research National Nutrition and Food Technology Research Institute, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Science Tehran Iran
                [ 7 ] School of Health Qazvin University of Medical Sciences Qazvin Iran
                [ 8 ] Nutrition Research Center, School of Nutrition and Food Sciences Shiraz University of Medical Sciences Shiraz Iran
                [ 9 ] Department of Pharmacologynosy, Faculty of Pharmacy Tehran University of Medical Sciences Tehran Iran
                [ 10 ] Department of Clinical Biochemistry, Faculty of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran
                [ 11 ] Nursing and Midwifery School Guilan University of Medical Sciences Rasht Iran
                [ 12 ] Department of Nutrition Research National Nutrition and Food Technology Research Institute, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences Tehran Iran
                [ 13 ] Department of Community Nutrition National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences Tehran Iran
                Author notes
                [*] [* ] Correspondence

                Saeid Doaei, Department of Community Nutrition, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

                Email: sdoaee@ 123456yahoo.com

                Mina Esmaili, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

                Email: minaesmaeili864@ 123456yahoo.com

                Author information
                https://orcid.org/0000-0002-2532-7478
                Article
                EDM2367 EDM2-2022-0081.R1
                10.1002/edm2.367
                9659656
                36039792
                52698015-3e3f-4fd1-afef-8e6cccbb610a
                © 2022 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 08 August 2022
                : 13 July 2022
                : 13 August 2022
                Page count
                Figures: 2, Tables: 3, Pages: 6, Words: 3849
                Funding
                Funded by: Shahid Beheshti University of Medical Sciences , doi 10.13039/501100005851;
                Funded by: National Nutrition and Food Technology Research Institute , doi 10.13039/501100008036;
                Funded by: National Nutrition and Food Technology Research Institute School of Nutrition Sciences and Food Technology Shahid Beheshti University of Medical Sciences, Tehran, Iran
                Award ID: 30204
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                November 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.0 mode:remove_FC converted:13.11.2022

                body mass index,liver enzyme,liver function,obesity
                body mass index, liver enzyme, liver function, obesity

                Comments

                Comment on this article